News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Singulex, Inc. Announces Two Studies Utilizing Company’s Proprietary System For Cardiovascular Risk Assessment At American Heart Association Scientific Sessions



11/13/2013 10:19:45 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced two studies using the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI) will be presented at the American Heart Association Scientific Sessions in Dallas, Texas.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES